NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism

Journal of Pathology

Volumn 230, Issue 1, 2013, Pages 82-94

  Zhu, Haifeng ^a   Vishwamitra, Deeksha ^a,b   Curry, Choladda V ^c   Manshouri, Roxsan ^a   Diao, Lixia ^a   Khan, Aarish ^a   Amin, Hesham M ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CTDSPL; iNOS; microRNA 26a; NPM ALK; STAT3; T cell lymphoma

Indexed keywords

ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MICRORNA; NITRIC OXIDE DONOR; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE; ONCOGENE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE; TRANSCRIPTION REGULATION; UPREGULATION;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMINES; LYMPHOMA, T-CELL; MICRORNAS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS; TYROSINE; UP-REGULATION;

EID: 84876118820     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4171     Document Type: Article

References (59)

1. + anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267.
2. Morris SW, Kirstein MN, Valentine MB, et al., Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
3. Morris SW, Naeve C, Mathew P, et al., ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-2188.
4. Chiarle R, Voena C, Ambrogio C, et al,. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Rev Cancer 2008; 8: 11-23.
5. Fujimoto J, Shiota M, Iwahara T, et al., Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A 1996; 93: 4181-4186.
6. Wellmann A, Doseeva V, Butscher W, et al., The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J 1997; 11: 965-972.
7. Kuefer MU, Look AT, Pulford K, et al., Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90: 2901-2910.
8. Chiarle R, Gong JZ, Guasparri I, et al., NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumours. Blood 2003; 101: 1919-1927.
9. Riera L, Lasorsa E, Ambrogio C, et al,. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem 2010; 285: 26441-26450.
10. Chikamori M, Fujiomto J, Tokai-Nishizumi N, et al,. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Oncogene 2007; 26: 2950-2954.
11. Bai RY, Dieter P, Peschel C, et al,. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998; 18: 6951-6961.
12. Bai RY, Ouyang T, Miething C, et al,. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway. Blood 2000; 96: 4319-4327.
13. Staber PB, Vesely P, Haq N, et al., The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 2007; 110: 3374-3383.
14. + anaplastic large-cell lymphoma. Blood 2009; 114: 360-370.
15. Chiarle R, Simmons WJ, Cai H, et al., Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Med 2005; 11: 623-629.
16. Lala PK, Chakraborty C,. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-156.
17. Fukumura D, Kashiwagi S, Jain RK,. The role of nitric oxide in tumour progression. Nature Rev Cancer 2006; 6: 521-534.
18. Palmer RM, Ferrige AG, Moncada S,. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
19. Lander HM, Sehajpal PK, Novogrodsky A,. Nitric oxide signaling: a possible role for G proteins. J Immunol 1993; 151: 7182-7187.
20. Genaro AM, Hortelano S, Alvarez A, et al,. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest 1995; 95: 1884-1890.
21. Beltrán B, Mathur A, Duchen MR, et al,. The effect of nitric oxide on cell respiration: a key to understanding its role in cell survival or death. Proc Natl Acad Sci U S A 2000; 97: 14602-14607.
22. Cho HJ, Xie Q-W, Calaycay J, et al., Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 1992; 176: 599-604.
23. Wink DA, Kasprzak KS, Maragos CM, et al., DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991; 254: 1001-1003.
24. Alatoma SH, Lipponen PK, Kosam VM,. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001; 21: 3101-3106.
25. Vakkala M, Kahlos K, Lakari E, et al,. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000; 6: 2408-2416.
26. Land SC, Rae C,. iNOS initiates and sustains metabolic arrest in hypoxic lung adenocarcinoma cells: mechanism of cell survival in solid tumor core. Am J Physiol Cell Physiol 2005; 289: C918-C933.
27. Fitzpatrick B, Mehiblel M, Cowen RL, et al,. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008; 19: 217-224.
28. Billard C, Menasria F, Quiney C, et al,. Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent. Leuk Res 2008; 32: 755-760.
29. Hammadi A, Billard C, Faussat A-M, et al,. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-κB activation. Nitric Oxide 2008; 19: 138-145.
30. Barreiro Arcos ML, Gorelik G, Klecha A, et al,. Inducible nitric oxide synthase-mediated proliferation of a T lymphoma cell line. Nitric Oxide 2003; 8: 111-118.
31. Li H-L, Sun B-Z, Ma F-C. Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2004; 10: 1862-1866.
32. Zhao H, Dugas N, Mathiot C, et al., B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998; 92: 1031-1043.
33. Levesque MC, Misukonis MA, O'Loughlin CW, et al., IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. Leukemia 2003; 17: 442-450.
34. Tiscornia AC, Cayota A, Landoni AI, et al., Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions. Leukemia 2004; 18: 48-56.
35. Drexler HG,. Guide to Leukemia-Lymphoma Cell Lines (2nd edn). German Collection of Microorganisms and Cell Cultures, Brauschweig, Germany, 2010.
36. Liu C-G, Calin GA, Volinia S, et al,. MicroRNA expression profiling using microarrays. Nature Protoc 2008; 3: 563-578.
37. Stone WL, Yang H, Qui M,. Assays for nitric oxide expression. Methods Mol Biol 2006; 315: 245-256.
38. Zamo A, Chiarle R, Piva R, et al., Anaplastic lymphoma kinase (ALK) activates STAT3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-1047.
39. 1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-5434.
40. Selleri C, Maciejewski JP, Montuori N, et al., Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood 2003; 102: 1490-1498.
41. Park S-Y, Baik YH, Cho JH, et al,. Inhibition of lipopolysaccharide- induced nitric oxide synthase through S6K1-p42/44 MAPK pathway and STAT3 (Ser 727) phosphorylation in Raw 262.7 cells. Cytokine 2008; 44: 126-134.
42. Lo HW, Hsu SC, Ali-Seyed M, et al., Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 575-589.
43. Yu Z, Zhang W, Kone BC,. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor κB. Biochem J 2002; 367: 97-105.
44. Yu Z, Kone BC,. The STAT3 DNA-binding domain mediates interaction with NF-κB p65 and inducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol 2004; 15: 585-591.
45. Linker K, Pautz A, Fechir M, et al,. Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP and TTP and HuR. Nucleic Acids Res 2005; 33: 4813-4827.
46. Fechir M, Linker K, Pautz A, et al., Tristetraprolin regulates the expression of human inducible nitric-oxide synthase gene. Mol Pharmacol 2005; 67: 2148-2161.
47. Kolodziejski PJ, Musial A, Koo J-S, et al. Ubiquitination of inducible nitric oxide synthase is required for its degradation. Proc Natl Acad Sci U S A 2002; 99: 12315-12320.
48. Guo Z, Shao L, Zheng L, et al,. miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes. Proc Natl Acad Sci U S A 2012; 109: 5826-5831.
49. Dai R, Phillips RA, Zhang Y, et al,. Suppression of LPS-induced interferon-γ and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood 2008; 112: 4591-4597.
50. Perske C, Lahat N, Levin SS, et al,. Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a. Am J Pathol 2010; 177: 2046-2054.
51. Desjobert C, Renalier M-H, Bergalet J, et al., MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 2011; 117: 6627-6637.
52. Matsuyama H, Suzuki HI, Nishimori H, et al., miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011; 118: 6881-6892.
53. Dejean E, Renalier MH, Fiosseau M, et al., Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma. Leukemia 2011; 25: 1882-1890.
54. Vishwamitra D, Li Y, Wilson D, et al., MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol 2012; 180: 1772-1780.
55. Chang T-C, Yu D, Lee Y-S, et al., Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genet 2007; 40: 43-50.
56. Huse JT, Brennan C, Hambardzumyan D, et al., The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009; 23: 1327-1337.
57. Zhang J, Han C, Wu T,. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology 2012; 143: 246-256.
58. Sander S, Bullinger L, Klapproth K, et al., MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-4212.
59. Varambally S, Cao Q, Mani RS, et al., Genomic loss of microRNA-101 leads to overexpression of methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.